Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2011

01-09-2011 | Short communication

Obituary: Joseph Lustgarten, 1963–2011

Authors: Suzanne Ostrand-Rosenberg, Esteban Celis, Peter Cohen, Zelig Eshher, Sandra Gendler, Dominique Hoelzinger, Arthur Hurwitz, Larry Pease, Linda Sherman, Lustgarten Lab Members

Published in: Cancer Immunology, Immunotherapy | Issue 9/2011

Login to get access

Excerpt

Dr. Joseph Lustgarten, our colleague, mentor, and friend died June 30, 2011 in Scottsdale, Arizona at the age of 48 from gastric cancer. …
Metadata
Title
Obituary: Joseph Lustgarten, 1963–2011
Authors
Suzanne Ostrand-Rosenberg
Esteban Celis
Peter Cohen
Zelig Eshher
Sandra Gendler
Dominique Hoelzinger
Arthur Hurwitz
Larry Pease
Linda Sherman
Lustgarten Lab Members
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1080-9

Other articles of this Issue 9/2011

Cancer Immunology, Immunotherapy 9/2011 Go to the issue

Original article

CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells

Original article

Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy

Original article

Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN

Review

Lung cancer and Toll-like receptors

Opinion Paper

Therapeutic effects of metformin in breast cancer: involvement of the immune system?

original article

Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits